Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum‐based treatment: A phase 1/2 trial

Documenti analoghi

• Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation reporta
  di: María Espinosa Bosch
  Pubblicazione: (2016)
• Efficacy of neoadjuvant chemotherapy combined with surgery in patients with nonsmall cell lung cancer: A meta‐analysis
  di: Hai‐jun Dong, et al.
  Pubblicazione: (2024)
• Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
  di: Maxime Borgeaud, et al.
  Pubblicazione: (2025)
• Efficacy of cross‐line anti‐programmed death 1/programmed cell death‐ligand 1 antibody in the treatment of advanced nonsmall cell lung cancer: A retrospective study
  di: Xiang Zhao, et al.
  Pubblicazione: (2024)
• Neoadjuvant therapy for patients with nonsmall cell lung cancer: Not as easy in the real world
  di: Giordano Fabricio Cittolin‐Santos, et al.
  Pubblicazione: (2026)